Watch Now: Replay of Our Urgent New Alert on India's Revival (Available Only Till Midnight Tonight)
Here is the latest financial fact sheet of Biocon. For more details, see the Biocon quarterly results and Biocon share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 2.1 |
No. of shares | m | 600.00 |
% ch week | % | -0.1 |
% ch 1-mth | % | 4.3 |
% ch 12-mth | % | 22.5 |
52 week H/L | Rs | 487.7/320.9 |
No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
---|
BIOCON EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 554 | 496 | 1,162 | 1,188 | 707 | |
Low | Rs | 407 | 397 | 483 | 305 | 554 | |
Sales per share (Unadj.) | Rs | 154.5 | 167.4 | 194.6 | 68.7 | 91.9 | |
Earnings per share (Unadj.) | Rs | 24.9 | 30.5 | 34.4 | 7.6 | 16.7 | |
Diluted earnings per share | Rs | 8.3 | 10.2 | 11.5 | 7.6 | 16.7 | |
Cash flow per share (Unadj.) | Rs | 35.9 | 42.9 | 48.3 | 14.0 | 24.2 | |
Dividends per share (Unadj.) | Rs | 5.00 | 5.00 | 1.00 | 1.00 | 1.00 | |
Adj. dividends per share | Rs | 1.67 | 1.67 | 0.33 | 1.00 | 1.00 | |
Dividend yield (eoy) | % | 1.0 | 1.1 | 0.1 | 0.1 | 0.2 | |
Book value per share (Unadj.) | Rs | 163.1 | 201.7 | 241.9 | 86.3 | 101.6 | |
Adj. book value per share | Rs | 54.4 | 67.2 | 80.6 | 86.3 | 101.6 | |
Shares outstanding (eoy) | m | 200.00 | 200.00 | 200.00 | 600.00 | 600.00 | |
Bonus/Rights/Conversions | - | - | - | IS | - | ||
Price / Sales ratio | x | 3.1 | 2.7 | 4.2 | 10.9 | 6.9 | |
Avg P/E ratio | x | 19.3 | 14.6 | 23.9 | 98.9 | 37.7 | |
P/CF ratio (eoy) | x | 13.4 | 10.4 | 17.0 | 53.4 | 26.1 | |
Price / Book Value ratio | x | 2.9 | 2.2 | 3.4 | 8.6 | 6.2 | |
Dividend payout | % | 20.1 | 16.4 | 2.9 | 13.2 | 6.0 | |
Avg Mkt Cap | Rs m | 96,080 | 89,220 | 164,440 | 447,900 | 378,330 | |
No. of employees | `000 | 7.5 | 4.4 | 9.2 | 6.1 | 6.1 | |
Total wages/salary | Rs m | 5,334 | 6,101 | 7,470 | 9,311 | 11,653 | |
Avg. sales/employee | Rs Th | 4,119.7 | 7,581.9 | 4,213.9 | 6,705.8 | 8,994.3 | |
Avg. wages/employee | Rs Th | 711.2 | 1,381.9 | 809.0 | 1,514.2 | 1,900.7 | |
Avg. net profit/employee | Rs Th | 663.2 | 1,379.6 | 745.2 | 736.9 | 1,635.3 |
BIOCON INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 30,898 | 33,474 | 38,911 | 41,234 | 55,144 | |
Other income | Rs m | 531 | 792 | 1,571 | 2,062 | 1,444 | |
Total revenues | Rs m | 31,429 | 34,266 | 40,482 | 43,296 | 56,588 | |
Gross profit | Rs m | 6,958 | 7,678 | 9,795 | 8,291 | 15,883 | |
Depreciation | Rs m | 2,210 | 2,487 | 2,772 | 3,851 | 4,478 | |
Interest | Rs m | 89 | 293 | 260 | 615 | 709 | |
Profit before tax | Rs m | 5,190 | 5,690 | 8,334 | 5,887 | 12,140 | |
Minority Interest | Rs m | -310 | 217 | 163 | 213 | 9 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 1,051 | 1,606 | 0 | 0 | 0 | |
Tax | Rs m | 957 | 1,422 | 1,616 | 1,569 | 2,123 | |
Profit after tax | Rs m | 4,974 | 6,091 | 6,881 | 4,531 | 10,026 | |
Gross profit margin | % | 22.5 | 22.9 | 25.2 | 20.1 | 28.8 | |
Effective tax rate | % | 18.4 | 25.0 | 19.4 | 26.7 | 17.5 | |
Net profit margin | % | 16.1 | 18.2 | 17.7 | 11.0 | 18.2 |
BIOCON BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 24,750 | 39,709 | 40,477 | 41,486 | 48,228 | |
Current liabilities | Rs m | 15,974 | 16,657 | 16,783 | 21,413 | 30,376 | |
Net working cap to sales | % | 28.4 | 68.9 | 60.9 | 48.7 | 32.4 | |
Current ratio | x | 1.5 | 2.4 | 2.4 | 1.9 | 1.6 | |
Inventory Days | Days | 56 | 59 | 60 | 64 | 68 | |
Debtors Days | Days | 81 | 78 | 83 | 94 | 86 | |
Net fixed assets | Rs m | 34,169 | 40,146 | 45,073 | 50,661 | 64,130 | |
Share capital | Rs m | 1,000 | 1,000 | 1,000 | 3,000 | 3,000 | |
"Free" reserves | Rs m | 31,622 | 39,338 | 47,377 | 48,808 | 57,980 | |
Net worth | Rs m | 32,622 | 40,338 | 48,377 | 51,808 | 60,980 | |
Long term debt | Rs m | 7,671 | 20,724 | 21,082 | 18,083 | 15,766 | |
Total assets | Rs m | 63,319 | 84,581 | 93,942 | 99,897 | 121,924 | |
Interest coverage | x | 59.3 | 20.4 | 33.1 | 10.6 | 18.1 | |
Debt to equity ratio | x | 0.2 | 0.5 | 0.4 | 0.3 | 0.3 | |
Sales to assets ratio | x | 0.5 | 0.4 | 0.4 | 0.4 | 0.5 | |
Return on assets | % | 8.0 | 7.5 | 7.6 | 5.2 | 8.8 | |
Return on equity | % | 15.2 | 15.1 | 14.2 | 8.7 | 16.4 | |
Return on capital | % | 14.9 | 12.8 | 12.6 | 9.6 | 16.8 | |
Exports to sales | % | 33.5 | 32.0 | 33.4 | 29.2 | 28.1 | |
Imports to sales | % | 19.7 | 21.2 | 20.3 | 17.8 | 18.9 | |
Exports (fob) | Rs m | 10,339 | 10,717 | 12,988 | 12,058 | 15,506 | |
Imports (cif) | Rs m | 6,102 | 7,105 | 7,899 | 7,348 | 10,399 | |
Fx inflow | Rs m | 10,993 | 11,789 | 12,988 | 12,058 | 15,506 | |
Fx outflow | Rs m | 7,371 | 8,445 | 7,899 | 7,348 | 10,399 | |
Net fx | Rs m | 3,622 | 3,344 | 5,089 | 4,710 | 5,107 |
BIOCON CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 2,107 | 3,706 | 6,400 | 6,621 | 11,546 | |
From Investments | Rs m | -5,087 | -11,417 | -4,985 | -6,840 | -7,138 | |
From Financial Activity | Rs m | 1,862 | 10,676 | -1,775 | -2,397 | -2,417 | |
Net Cashflow | Rs m | -1,118 | 3,000 | -473 | -2,612 | 2,103 |
Share Holding
|
Company Information
|
CHM: Kiran Mazumdar Shaw (MD) | COMP SEC: Kiran Kumar | YEAR OF INC: 1978 | BSE CODE: 532523 | FV (Rs): 5 | DIV YIELD (%): 0.2 |
More Pharmaceuticals Company Fact Sheets: NEULAND LABS J.B.CHEMICALS DR. REDDYS LAB PIRAMAL ENTERPRISES IPCA LABS
Compare BIOCON With: NEULAND LABS J.B.CHEMICALS DR. REDDYS LAB PIRAMAL ENTERPRISES IPCA LABS
Compare BIOCON With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.
More